Download PDF
Thromb Haemost 1980; 44(03): 138-142
DOI: 10.1055/s-0038-1650104
Original Article
Schattauer GmbH Stuttgart

Evaluation of the Effect of Betapropiolactone/Ultraviolet Irradiation (BPL/UV) Treatment of Source Plasma on Hepatitis Transmission by Factor IX Complex in Chimpanzees

Alfred M Prince
1   The Lindsley F. Kimball Research Institute of The New York Blood Center, New York, and Dept. of Pathology, New York Hospital/Cornell Medical Center
,
W Stephan
2   The Biotest Serum Institute, GmbH, Frankfurt (Main), West Germany
,
B Brotman
1   The Lindsley F. Kimball Research Institute of The New York Blood Center, New York, and Dept. of Pathology, New York Hospital/Cornell Medical Center
3   The Vilab II, The Liberian Institute for Biomedical Research, Robertsfield, Liberia
,
M C van den Ende
1   The Lindsley F. Kimball Research Institute of The New York Blood Center, New York, and Dept. of Pathology, New York Hospital/Cornell Medical Center
3   The Vilab II, The Liberian Institute for Biomedical Research, Robertsfield, Liberia
› Author Affiliations
Further Information

Publication History

Received 12 May 1980

Accepted 25 September 1980

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

To evaluate the safety of a β-Propiolactone/Ultraviolet (BPL/UV), irradiated Factor IX complex preparation we inoculated 8 chimpanzees with 25 units Factor IX/Kilo from a pool of 5 production lots which had been treated in this manner. These lots were derived from approximately 1,000 donors. Animals were followed with weekly tests for hepatitis B serologic markers and transaminases, and biweekly liver biopsies, for 6 months. No evidence of transmission of hepatitis B, or non-A, non-B viruses was observed.

To further evaluate the BPL/UV procedure a plasma pool was intentionally contaminated with hepatitis B virus and one half of the pool treated with BPL/UV. Factor IX complex was isolated from the treated and untreated pools and each was inoculated into 4 chimpanzees. The Factor IX derived from untreated plasma infected all four animals with an average incubation period of 10.5 weeks, whereas that prepared from BPL/UV treated plasma infected only one of four animals with an incubation period of 21 weeks. These results were interpreted as suggesting that BPL/UV can inactivate approximately 99.9% of hepatitis B virus infectivity.

Key words

Factor IX complex - Hepatitis viruses-β-propiolactone
 

  • References

  • 1 Boklan BF. Factor IX concentrate and viral hepatitis. Ann Intern Med 1971; 74: 298
    PubMedGoogle Scholar
  • 2 Faria R, Fiumara NJ. Hepatitis B associated with Konyne. New Engl J Med 1972; 287: 358-359
    PubMedGoogle Scholar
  • 3 Hellerstein LJ, Deykin D. Hepatitis after Konyne administration. New Engl J Med 1971; 284: 1039-1040
    PubMedGoogle Scholar
  • 4 Iwarson S, Kjellman H, Teger-Nilsson AC. Incidence of viral hepatitis after administration of Factor IX concentrates. Vox Sang 1976; 31: 136-140
    CrossrefPubMedGoogle Scholar
  • 5 Oken MM, Hootkin L, DeJager RL. Hepatitis after Konyne administration. Am J Dig Dis 1972; 17: 271-274
    CrossrefPubMedGoogle Scholar
  • 6 Sandler SG, Rath CE, Wickerhauser M, Dodd RJ, Greenwalt TJ. Post Konyne hepatitis. The ineffectiveness of screening for the hepatitis B antigen (HB Ag). Transfusion 1973; 13: 221-223
    CrossrefPubMedGoogle Scholar
  • 7 Heystek J, Brummelhuis HG J, Krijnen HW. Contributions to the optimal use of human blood. II. The large-scale preparation of prothrombin complex. A comparison between two methods using the anion exchangers DEAE-cellulose DE 52 and DEAE-Sephadex A 50. Vox Sang 1973; 25: 113-123
    CrossrefPubMedGoogle Scholar
  • 8 Ohlmeier H, Dahmen E, Hoppe I. Hepatitisrisiko von humanen Gerinnungspräparaten aus gepoolten Plasmen. Ergebnisse einer Prospektivstudie. Dtsch Med Wochenschr 1978; 103: 1700-1703
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Hoofnagle JH, Gerety RJ, Thiel J, Barker LF. The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med 1976; 88: 102-113
    PubMedGoogle Scholar
  • 10 Craske J, Dilling N, Stern D. An outbreak of hepatitis associated with intravenous injection of Factor VIII concentrate. Lancet 1975; ii: 221-223
    PubMedGoogle Scholar
  • 11 Hruby MA, Schauf V. Transfusion related short incubation hepatitis in hemophiliac patients. J Am Med Assoc 1978; 240: 1355-1357
    CrossrefPubMedGoogle Scholar
  • 12 Kotitschke R, Stephan W. Kombinierte Behandlung von Gerinnungsfaktoren in Humanplasma mit ß-Propiolacton und UV. Struktur und Funktion des Fibrinogens: Blutgerinnung und Mikrozirkulation. 1976. Stuttgart, New York: F K Schattauer:: Pp 222-228
    Google Scholar
  • 13 Kotitschke R, Stephan W. In vivo recovery Studien von Prothrombinkomplexkonzentraten an Ratten. Immunologische Probleme der Blutgerinnung. 1978. Stuttgart, New York: F K Schattauer Verlag: Pp 317-324
    Google Scholar
  • 14 Hartmann FW, LoGrippo GA. Combined beta-propiolactone and ultraviolet irradiation for plasma sterilization. Hepatitis Frontiers, Henry-Ford-Hospital, International Symposium. 1957. Boston, Toronto: Little, Brown and Co.:: Pp 407-416
    Google Scholar
  • 15 Stephan W, May G. Adsorption von coli-phagen. Z Klin Chem 1968; 6: 191-192
    PubMedGoogle Scholar
  • 16 LoGrippo GA, Hayashi H. Efficacy of betaprone with ultraviolet irradiation on hepatitis B antigen in human plasma pools. Henry-Ford-Hospital, Med J 1973; 21: 181-186
    PubMedGoogle Scholar
  • 17 Stephan W, Kotitschke R. Prothrombinkomplexkonzentrat aus kaltsterilisiertem Plasma. Forschungsergebnisse der Transfusion und Immunohaematologie 1977; 4: 72-75
    PubMedGoogle Scholar
  • 18 Stephan W. Hepatitis-free and stable human serum for intravenous therapy. Vox Sang 1971; 20: 442-457
    CrossrefPubMedGoogle Scholar
  • 19 Kornhuber B. Studie zur Hepatitissicherheit von Biseko. Biotest Mitteilungen 1974; 35: 44-45
    PubMedGoogle Scholar
  • 20 Barker LF, Maynard JE, Purcell RH, Hoofnagle JH, Berquist KR, London WT, Gerety RJ, Krushak DH. Hepatitis B virus infection in chimpanzees: titration of subtypes. J Infect Dis 1975; 132: 451-458
    CrossrefPubMedGoogle Scholar
  • 21 Alter JH, Purcell RH, Holland PV, Popper H. Evidence for a transmissible agent in non-A, non-B hepatitis. Lancet 1978; i: 459-463
    PubMedGoogle Scholar
  • 22 Hollinger FB, Gitnick GL, Aach RD, Szmuness W, Mosley JW, Stevens CE, Peters RL, Weiner JM, Werch JB, Lander JJ. Non-A, non-B hepatitis transmission in chimpanzees: a project of the transfusion-transmitted viruses study group. Intervirology 1978; 10: 60-68
    CrossrefPubMedGoogle Scholar
  • 23 Prince AM, Brotman B, Van den Ende MC, Richardson L, Kellner A. Non-A, non-B hepatitis: identification of a virus specific antigen and antibody. A preliminary report. Viral Hepatitis 1978. Vyas GN, Cohen N, Schmid R. Phil.: Franklin Institute Press: Pp 633-642
    Google Scholar
  • 24 Tabor E, Gerety RJ, Drucker JA, Seeff LB, Hoofnagle JH, Jackson DR, April M, Pineda-Tamondong G, Barker LF. Evidence for a transmissible agent in human non-A, non-B hepatitis. Experimental transmission to chimpanzees by human sera. Lancet 1978; i: 463-465
    PubMedGoogle Scholar
  • 25 Prince AM, Brotman B, Richardson L. Detection of "non-specific" cross reacting anti-HBs activity by the Ausab RIA. Viral Hepatitis. 1978. Vyas GN, Cohen N, Schmid R. Phil.: Franklin Institute Press: p 732-733
    Google Scholar
  • 26 Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, Imai M, Mayumi M, Moritsugu Y. Hepatitis B antigen and infectivity of hepatitis B virus. J Infect Dis 1977; 136: 571-576
    CrossrefPubMedGoogle Scholar